NCT06346600

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 83 (estimated)
• Sponsor: Skyline Therapeutics · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.

Conditions

• Neovascular (Wet) Age-related Macular Degeneration

Interventions

Type	Name	Description
GENETIC	SKG0106	Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.

Timeline

• Start date: 2024-04-02
• Primary completion: 2031-03-01
• Completion: 2031-03-01
• First posted: 2024-04-04
• Last updated: 2024-04-04

Locations

10 sites across 2 countries: United States, China

Regulatory

• FDA-regulated drug study